2025 Q4 -tulosraportti
56 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
29,15%Tuotto/v
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 475 | - | - | ||
| 2 267 | - | - | ||
| 2 012 | - | - | ||
| 4 485 | - | - | ||
| 1 034 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sittenNykode is now looking for a Lab Technician (until March 2027) to take care of logistics, equipment, and prep-work at the lab in Oslo. Why is this a strong signal? Frees up time: By letting support staff handle daily operations, top researchers can focus 100 % on USA data and the Abili-T study. Full speed ahead: You don't hire people for an intensive race until 2027 if the coffers are empty or the pace is to slow down. Here, it's being built stone by stone while we wait for the next stock price surge! Https://www.finn.no/job/ad/460906176
10 t sitten10 t sittenGuys enjoy a journey with fantastic background !!!7 t sitten7 t sittenWell as You have seen results, company in not such a risk anymore and we are dealing with platform and not just one study :) That already say something. Of course news about Phase 2 are not just randon aswell plus as you for sure know conpany have secured cash and reduced burning
·14 t sitten- 1 päivä sitten1 päivä sitten◦ Today at #AACR2026, our senior scientist, Ingvild Sørum Leikfoss presented additional immunogenicity data from our VB-C-03 trial and the results are compelling. 100% of evaluable patients in the 6 mg and 9 mg dose groups showed HPV16-specific T-cell immune responses to abi-suva in combination with pembrolizumab. Responses were rapid, robust and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment. Our VB-C-03 trial demonstrated a confirmed objective response rate of 38.5% in patients with HPV16+ recurrent or metastatic head and neck cancer, where standard of care achieves an obiective response rate of only ~19% and we believe abi-suva can make a real difference for these patients., These data give us strong confidence as we move into the Abili-T Phase Il randomized trial G The poster is available for viewing in the "R&D" section of Nykode's website https://lnkd.in/eh4Nrx76 #Nykode #abisuva #HNSCC #HPV16 #CancerVaccine #lmmunotherapy #AACR2026 https://www.linkedin.com/posts/nykode_scientific-papers-and-presentations-nykode-activity-7452434758468456448-V-cn?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU
·1 päivä sittenAnything new since yesterday?·23 t sittenTonight, the actual data was presented at the AACR conference. Here's the most important: Double effect: The data confirms an objective response rate (ORR) of 38.5%. In comparison, today's standard treatment only yields ~19%. Nykode thus doubles the effect. Dose selection: They have now locked the dosage to 6 mg and 9 mg. The data showed that 100% of patients in these groups achieved a strong and lasting immune response. T-cell proof: New graphs (TCR sequencing) prove that the vaccine creates many different types of 'soldiers' that survive in the blood throughout the entire treatment. This is technically impressive and distinguishes them from competitors. Operational status: They confirmed tonight that the study centers are now open, and they maintain the goal of the first patient dosed now in Q2 2026. Yesterday we learned that things were going well – tonight we received the scientific evidence for why things are going so well!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
56 päivää sitten
‧36 min
1,00 NOK/osake
Viimeisin osinko
29,15%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenNykode is now looking for a Lab Technician (until March 2027) to take care of logistics, equipment, and prep-work at the lab in Oslo. Why is this a strong signal? Frees up time: By letting support staff handle daily operations, top researchers can focus 100 % on USA data and the Abili-T study. Full speed ahead: You don't hire people for an intensive race until 2027 if the coffers are empty or the pace is to slow down. Here, it's being built stone by stone while we wait for the next stock price surge! Https://www.finn.no/job/ad/460906176
- 10 t sitten10 t sittenGuys enjoy a journey with fantastic background !!!7 t sitten7 t sittenWell as You have seen results, company in not such a risk anymore and we are dealing with platform and not just one study :) That already say something. Of course news about Phase 2 are not just randon aswell plus as you for sure know conpany have secured cash and reduced burning
- ·14 t sitten
- 1 päivä sitten1 päivä sitten◦ Today at #AACR2026, our senior scientist, Ingvild Sørum Leikfoss presented additional immunogenicity data from our VB-C-03 trial and the results are compelling. 100% of evaluable patients in the 6 mg and 9 mg dose groups showed HPV16-specific T-cell immune responses to abi-suva in combination with pembrolizumab. Responses were rapid, robust and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment. Our VB-C-03 trial demonstrated a confirmed objective response rate of 38.5% in patients with HPV16+ recurrent or metastatic head and neck cancer, where standard of care achieves an obiective response rate of only ~19% and we believe abi-suva can make a real difference for these patients., These data give us strong confidence as we move into the Abili-T Phase Il randomized trial G The poster is available for viewing in the "R&D" section of Nykode's website https://lnkd.in/eh4Nrx76 #Nykode #abisuva #HNSCC #HPV16 #CancerVaccine #lmmunotherapy #AACR2026 https://www.linkedin.com/posts/nykode_scientific-papers-and-presentations-nykode-activity-7452434758468456448-V-cn?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU·1 päivä sittenAnything new since yesterday?·23 t sittenTonight, the actual data was presented at the AACR conference. Here's the most important: Double effect: The data confirms an objective response rate (ORR) of 38.5%. In comparison, today's standard treatment only yields ~19%. Nykode thus doubles the effect. Dose selection: They have now locked the dosage to 6 mg and 9 mg. The data showed that 100% of patients in these groups achieved a strong and lasting immune response. T-cell proof: New graphs (TCR sequencing) prove that the vaccine creates many different types of 'soldiers' that survive in the blood throughout the entire treatment. This is technically impressive and distinguishes them from competitors. Operational status: They confirmed tonight that the study centers are now open, and they maintain the goal of the first patient dosed now in Q2 2026. Yesterday we learned that things were going well – tonight we received the scientific evidence for why things are going so well!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 475 | - | - | ||
| 2 267 | - | - | ||
| 2 012 | - | - | ||
| 4 485 | - | - | ||
| 1 034 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
2025 Q4 -tulosraportti
56 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 27.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 25.2. | ||
2025 Q3 -tulosraportti 24.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 | ||
2024 Q4 -tulosraportti 26.2.2025 |
1,00 NOK/osake
Viimeisin osinko
29,15%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sittenNykode is now looking for a Lab Technician (until March 2027) to take care of logistics, equipment, and prep-work at the lab in Oslo. Why is this a strong signal? Frees up time: By letting support staff handle daily operations, top researchers can focus 100 % on USA data and the Abili-T study. Full speed ahead: You don't hire people for an intensive race until 2027 if the coffers are empty or the pace is to slow down. Here, it's being built stone by stone while we wait for the next stock price surge! Https://www.finn.no/job/ad/460906176
- 10 t sitten10 t sittenGuys enjoy a journey with fantastic background !!!7 t sitten7 t sittenWell as You have seen results, company in not such a risk anymore and we are dealing with platform and not just one study :) That already say something. Of course news about Phase 2 are not just randon aswell plus as you for sure know conpany have secured cash and reduced burning
- ·14 t sitten
- 1 päivä sitten1 päivä sitten◦ Today at #AACR2026, our senior scientist, Ingvild Sørum Leikfoss presented additional immunogenicity data from our VB-C-03 trial and the results are compelling. 100% of evaluable patients in the 6 mg and 9 mg dose groups showed HPV16-specific T-cell immune responses to abi-suva in combination with pembrolizumab. Responses were rapid, robust and durable, with a demonstrated persistence into the last analyzed timepoint at the completed end-of-treatment. Our VB-C-03 trial demonstrated a confirmed objective response rate of 38.5% in patients with HPV16+ recurrent or metastatic head and neck cancer, where standard of care achieves an obiective response rate of only ~19% and we believe abi-suva can make a real difference for these patients., These data give us strong confidence as we move into the Abili-T Phase Il randomized trial G The poster is available for viewing in the "R&D" section of Nykode's website https://lnkd.in/eh4Nrx76 #Nykode #abisuva #HNSCC #HPV16 #CancerVaccine #lmmunotherapy #AACR2026 https://www.linkedin.com/posts/nykode_scientific-papers-and-presentations-nykode-activity-7452434758468456448-V-cn?utm_source=share&utm_medium=member_android&rcm=ACoAAGGSC24B2EXoI8xUZIcaQ9SFwUPmSQJHIyU·1 päivä sittenAnything new since yesterday?·23 t sittenTonight, the actual data was presented at the AACR conference. Here's the most important: Double effect: The data confirms an objective response rate (ORR) of 38.5%. In comparison, today's standard treatment only yields ~19%. Nykode thus doubles the effect. Dose selection: They have now locked the dosage to 6 mg and 9 mg. The data showed that 100% of patients in these groups achieved a strong and lasting immune response. T-cell proof: New graphs (TCR sequencing) prove that the vaccine creates many different types of 'soldiers' that survive in the blood throughout the entire treatment. This is technically impressive and distinguishes them from competitors. Operational status: They confirmed tonight that the study centers are now open, and they maintain the goal of the first patient dosed now in Q2 2026. Yesterday we learned that things were going well – tonight we received the scientific evidence for why things are going so well!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 475 | - | - | ||
| 2 267 | - | - | ||
| 2 012 | - | - | ||
| 4 485 | - | - | ||
| 1 034 | - | - |
Välittäjätilasto
Dataa ei löytynyt